Serono gets Raptiva license

Serono (SRA; SWX:SEO) will receive an exclusive marketing license from Genentech (DNA) to Raptiva efalizumab (formerly Xanelim), in all countries outside the U.S., Japan and certain other Asian countries. Raptiva, a T cell modulator antibody, is in Phase III trials to treat moderate to severe plaque psoriasis. SRA expects to submit an MAA in the first quarter of 2003 and to launch the compound in Europe in 2004. ...